CDH1 and cancer: In addition to its individual effect on cancer cells, some studies have shown that garcinol is a suitable compound for combination therapy due to its ability to sensitize cells resistant to erlotinib and cisplatin and reduce TGF-β1-induced EMT (increased expression of E-cadherin and downregulation of N-cadherin and vimentin), probably by affecting the expression of EMT-modulating miRNAs [237].